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1.0 Abstract 1 
Objectives: Previous research has identified the effectiveness of third wave 2 
therapies in reducing the symptoms of a variety of physical and psychological 3 
presentations. This systematic review will assess the efficacy of third wave 4 
therapies for adults with neurodegenerative diseases. 5 
Methods: The selected electronic databases, Medline, PsychInfo, Embase and 6 
Cinahl, were used to search for studies that were published from the inception 7 
of each database to January 2018. Third wave therapies (e.g. Acceptance and 8 
Commitment Therapy, Dialectical Behaviour Therapy, Mindfulness-Based 9 
Cognitive Therapy) and neurodegenerative diseases (e.g. Alzheimer disease, 10 
Parkinson’s disease, Prion disease) were included as search terms.    11 
Results: The systematic literature search revealed 570 potentially relevant 12 
papers. From this number, seven studies were found to be eligible for inclusion 13 
in the narrative synthesis. These studies reported on four neurodegenerative 14 
diseases and five adapted third wave therapy interventions. There were found 15 
to be mixed results on the effectiveness of third wave therapies for improving 16 
both physical and psychological symptoms in a variety of neurodegenerative 17 
diseases. 18 
Conclusions: At this stage, it is not possible to deem whether third wave 19 
therapies are feasible in offering psychological or physical benefits to the 20 
neurodegenerative disease population. However, despite not being able to 21 
draw any firm conclusions, the use of third wave therapies has shown some 22 
potential benefits. Further randomised controlled trials to assess the 23 
effectiveness of adapted third wave therapies are required.  24 





Practitioner Points 2 
+ Three studies identified improvements in cognitive functioning in the 3 
intervention group in comparison with the control group. 4 
+ Some studies also found improvements in anxiety, depression, quality of life, 5 
and mindfulness following third wave therapy interventions.  6 
- However, an increase in depression, stress and a reduction in quality of life 7 
found following third wave therapies. 8 
- As this is the first review of this population and third wave therapies, it has 9 
not been possible to focus more closely on just one specific third wave therapy 10 
or neurodegenerative disease. Further research on the effectiveness of third 11 








2.0 Introduction 20 
2.1 Neurodegenerative disease 21 




Neurodegenerative disease is an umbrella term for various degenerative 1 
conditions. The most common are Alzheimer disease, Parkinson disease, 2 
Lewy body dementia, Frontotemporal dementia. The etiology of 3 
neurodevelopmental diseases has been suggested to be the influence of 4 
environmental factors (e.g. exposure to toxins), genetic susceptibility (e.g. 5 
inheritance of genetic mutation) and ageing (Braak, Rüb, Gai, Del Tredici, 6 
2003; Halliwell, 2006). The disease progression is irreversible, there is no cure, 7 
and available medical treatments can be very limited in their ability to slow 8 
down the gradual degeneration process (Carr, 2006; Weintraub, Comella & 9 
Horn, 2008).  10 
The pathophysiological process of neurodegenerative disease development is 11 
due to proteins within neurons, which both exist within the central nervous 12 
system, mutating and deteriorating in their ability to function. The proteins do 13 
not repair themselves and cannot be replaced, which then progressively leads 14 
to the deterioration of the brain and the spinal cord (Bertram & Tanzi, 2005; 15 
Moussaud et al., 2014).  16 
The principal deterioration characteristic of neurodegenerative diseases is 17 
dementia; a loss of neurocognitive functioning (e.g. memory, recall and 18 
reasoning) caused by structural changes to the brain. Alzheimer disease, 19 
which is characterised by a gradual global cognitive decline, is the most 20 
common form of dementia representing up to 70% of cases. The disease can 21 
cause a reduction in executive functioning skills, such as selective attention, 22 
planning and working memory (Carr, 2006; Bechara, Damasio, Damasio & 23 
Anderson, 1994; Bertram & Tanzi, 2005). Other symptoms commonly 24 
exhibited include language deficits (e.g. transcortical sensory aphasia, 25 




paraphasia, anomic aphasia) and during the later stages of the disease, 1 
myoclonus (e.g. ticks and jerks) and seizures (Krauss & Mathews, 2003).  2 
Parkinson’s disease, regarded as the second most common 3 
neurodegenerative disease, is largely characterised by motor ability 4 
deterioration (e.g. tremors and rigidity). Parkinson’s disease dementia is also 5 
characterised by cognitive deficits (e.g. memory and information processing 6 
skills), but in comparison to other dementias, it is one the least prevalent at 7 
approximately 2% of all dementia diagnoses (Carr, 2006; Bertram & Tanzi, 8 
2005; Schoenberg & Scott, 2011). 9 
Lewy body dementia is the second most common form of dementia behind 10 
Alzheimer disease. It potentially accounts for up to 15% of adults with 11 
dementia, but due to its pathological overlap with AD and PD dementia, it is 12 
often not possible to diagnose it until an autopsy is performed. Symptoms can 13 
consist of motor deficits similar to those exhibited in Parkinson disease, as well 14 
as visual and auditory hallucinations and cognitive deterioration (Bertram & 15 
Tanzi, 2005; Schoenberg & Scott, 2011). 16 
In frontal lobe dementia, deterioration is also associated with language, 17 
personality and behavioural changes as the disease progression causes 18 
lesions on key areas such as the orbitofrontal cortex and the dorsolateral 19 
prefrontal cortex, areas which are associated with impulsivity and decision 20 
making (Torregrossa, Quinn, & Taylor, 2008). Personality changes have been 21 
found to be an exacerbation of a person’s premorbid personality construct. 22 
Therefore, prior traits of anger, anxiety, or depression increase in severity and 23 
frequency as the neurodegenerative disease progresses.  24 




The remaining neurodegenerative diseases (e.g. Prion disease, Motor 1 
neurone diseases, Huntington’s disease) exhibit a variety of the above 2 
symptoms to differing levels of intensity and severity. Although similar in their 3 
symptomology, differentiations can be made between neurodegenerative 4 
diseases based on a person’s functioning during deterioration (Schoenberg & 5 
Scott, 2011). 6 
2.2 Psychological difficulties 7 
Neurodegenerative diseases contribute to the development of psychological 8 
difficulties, as the frustrating and life changing symptoms, lead to a reduction 9 
of independence and quality of life. The burden on adults with 10 
neurodegenerative diseases and their families is substantial, as is the 11 
economic cost of care and support (Dowding, Shenton & Salek, 2006; Olesen, 12 
Gustavsson, Svensson, Wittchen, & Jönsson, 2012; Wimo, Jönsson, Bond, 13 
Prince, & Winblad, 2013).  14 
The World Population Ageing report (United Nations, 2015) has estimated that 15 
in the next twelve years the number of adults over the age of 60 will grow by 16 
over 50%. With this growth, so to comes the need for increased physical and 17 
psychological support surrounding age related diseases.  18 
A variety of psychological therapies with a cognitive (e.g. learning new 19 
strategies), emotional (e.g. communication of feelings) and behavioural (e.g. 20 
self-care) person-centred focus for adults with neurodegenerative diseases 21 
and their carers have been found to be successful in improving quality of life 22 
(Brooker & Latham, 2015; Molloy, 2016: Pinquart, & Forstmeier, 2012). 23 




However, limited focus has been paid to the effectiveness and benefits of third 1 
wave therapies for adults with neurodegenerative diseases.  2 
2.3 Third wave therapies 3 
Third wave therapies include Dialectical Behaviour Therapy (DBT) (Linehan, 4 
1993), Acceptance and Commitment Therapy (ACT) (Hayes, 2004), 5 
Mindfulness-Based Cognitive Therapy (MBCT) (Segal, Teasdale, Williams, 6 
Gemar, 2002) and Mindfulness-Based Stress Reduction (MBSR) (Kabat‐Zinn, 7 
2003). The characteristic that all third wave psychotherapies share is a focus 8 
on mindfulness and acceptance techniques, in which recognition, observation 9 
and acceptance of thoughts, feelings and situations occur, without an attempt 10 
to challenge or remove them. The aim instead is to increase a person’s 11 
behavioural skills so they are more prepared and reflective when reacting to 12 
negative cognitive processes (Forman & Herbert, 2009).  13 
The act of being mindful is achieved through a range of meditative practices 14 
including body scans, meditation of the breath and mindful movement. It has 15 
been found to be beneficial as a means of improving attentional control, affect 16 
regulation, body awareness, and changing perception of the self (Hölzel et al., 17 
2011). There is also evidence to suggest that accepting and recognising both 18 
positive and negative experiences rather than avoiding them, is both physically 19 
and psychologically beneficial (Kuyken et al., 2010). 20 
Third wave therapies have been introduced as a treatment for a variety of 21 
physical health problems (e.g. eating disorders), neurological (e.g. multiple 22 
sclerosis) and mental health problems, with National Institute for Health and 23 
Care Excellence (NICE) guidelines recommending the use of Mindfulness 24 




Based Cognitive Therapy (MBCT) as a treatment for chronic depression 1 
(Hofmann, Sawyer, Witt & Oh, 2010; Kahl, Winter & Schweiger, 2012; 2 
Kristeller & Wolever, 2010; NICE, 2009; Simpson et al., 2014). Third wave 3 
therapies have also been used as a means to improve quality of life and well-4 
being in non-clinical samples (Fisak & von Lehe, 2012).  5 
2.4 Rationale  6 
Previously conducted randomised controlled trials (RCT) have investigated the 7 
physical and psychological benefits that third wave therapies offer to individual 8 
neurodegenerative disease diagnoses. However, a comprehensive systematic 9 
review of third wave therapies for a variety of neurodegenerative disease 10 
diagnoses has not been completed, and would be a useful addition to the 11 
knowledge base.  12 
Therefore, the purpose of the systematic review is to include and review any 13 
RCT’s that use third wave interventions to improve outcomes in adults with a 14 
neurodegenerative disease. The aims are to: 1) examine the effectiveness of 15 
third wave therapies in improving outcomes in neurodegenerative diseases, 2) 16 
identify which third wave therapies have been used with which 17 
neurodegenerative disease diagnoses, 3) identify which third wave therapy 18 
shows the most beneficial outcomes, 4) assess the strength of the evidence 19 
for the benefit of third wave therapies for the neurodegenerative disease 20 
population, 5) establish any weaknesses in the studies reviewed, and any 21 
potential future research recommendations.   22 
2.5 Objective 23 




The systematic literature review aims to examine the effect of third wave 1 
therapies in improving physical and psychological outcomes, such as 2 
improved quality of life, ability to cope and management of symptoms, 3 



















3.0 Methodology 23 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 24 
(PRISMA) guidelines and other systematic review guidelines (Dempster, 2011; 25 




Jahan, Naveed, Zeshan, Tahir, 2016) were followed in designing, extracting 1 
data and reporting the review.  2 
3.1 Eligibility criteria 3 
Studies were included in the review if: 1) they investigated third wave therapy 4 
interventions for participants with a neurodegenerative disease of any severity, 5 
2) they reported pre and post quantitative measures of psychological (e.g. 6 
emotional, cognitive, interpersonal or behavioural) or physical outcomes, 3) 7 
they included a comparison group of participants who did not participate in a 8 
third-wave therapy, including participants in a waiting-list/usual care control 9 
group, 4) the participants were adults, 5) the studies were reported in English.  10 
3.2 Information sources and search methods 11 
The selected electronic databases, Medline, PsychInfo, Embase and Cinahl, 12 
were used to search for studies that were published from the inception of each 13 
database to January 2018. The third wave therapies selected for inclusion in 14 
the review were in accordance with a recent meta-analysis of third wave 15 
cognitive and behavioural therapies (e.g. Acceptance and Commitment 16 
Therapy, Dialectical Behaviour Therapy, Mindfulness-Based Cognitive 17 
Therapy) (Dimidjian et al., 2016). The term “contextual cognitive behavioural 18 
therapy” was also included in the search as it had recently been identified as 19 
a new name for third wave therapy (Hayes, Villatte, Levin & Hildebrandt, 2011).  20 
The neurodegenerative disease terms (e.g. Alzheimer disease, Parkinson’s 21 
disease, Prion disease) used for the search followed the diagnoses identified 22 
by the EU joint programme for neurodegenerative disease (JPND) (Joint 23 
programme for neurodegenerative disease, 2018). The “neurodegenerative 24 




disease” and “third wave therapy” search terms were customised for each 1 
database and combined using the word “and”. The results from each database 2 
were saved in RefWorks (ProQuest). The search strategy for each database 3 
is in appendix A. 4 
3.3 Data collection process 5 
Two authors reviewed (using the eligibility criteria), firstly, the title and abstract 6 
of all hits from the electronic search and, secondly, the full texts of any hits that 7 
were agreed to be eligible on the basis of the title/abstract screen. Relevant 8 
data was systematically extracted from the full articles, including methods, 9 
participant information, interventions and outcomes (table 1 and 2). All authors 10 
reviewed the data and disagreements were resolved through discussions.  The 11 
inter-rater agreement rate was 95%, and this high level of agreement is 12 
supported by a Cohen’s kappa value of 0.75, p < .001. 13 
3.4 Quality assessment 14 
The quality of the studies was reviewed using the “Quality Assessment Tool 15 
for Quantitative Studies” (Effective Public Health Practice Project, 1998). For 16 
the review, the tool was used to synthesise knowledge about each study’s 17 
quality (e.g. study design, blinding, intervention integrity) to produce an overall 18 
methodology rating of strong, moderate or weak (table 2). 19 
3.5 Analysis 20 
A narrative synthesis was conducted due to the lack of homogeneity in the 21 
quantitative measures and interventions between the reviewed studies.  22 
 23 

















4.0 Results 14 
Figure 1 – Study selection flow chart (from: Moher, Liberati, Tetzlaff, Altman, 2009) 15 





Records identified through 
database searching  







Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 373) 

















RCT=randomised controlled trial 14 
 15 
4.1 Study selection 16 
The systematic literature search revealed 570 potentially relevant papers. 17 
From this number, 197 duplicates were removed, leaving 373 titles and 18 
abstracts to be reviewed. From here, 345 papers were removed as they were 19 
not eligible, so that 28 papers received a full text screening, which led to the 20 
identification of 7 studies that were found to be eligible for inclusion in the 21 
















Records screened  
(n = 373) 
Records excluded  
(n = 345) 
Full-text articles assessed 
for eligibility  
(n = 28) 
Full-text articles excluded, with 
reasons  
(n = 21) 
- 14 removed because they 
were not RCT’s. 
 
- 3 removed because they did 
not use a neurodegenerative 
disease population.  
 
- 2 removed as the full article 
was not in English.  
 
- 1 removed as it was a 
conference paper. 
 
- 1 removed as it did not use a 
third wave therapy.  
Studies included in 
qualitative synthesis  
(n = 7) 




completed in Belgium, one in the Netherlands, one in Italy, one in Australia, 1 
one in England and one in Spain.  2 
4.2 Study characteristics (table 1) 3 
4.2.1 Population 4 
Out of the seven studies included in the review, 474 participants were 5 
recruited, and the participants’ average age ranged between 59 and 86 years 6 
old. The studies reported on four neurodegenerative diseases, of which, four 7 
studies investigated Parkinson’s disease, one investigated Amyotrophic 8 
Lateral Sclerosis (ALS), one investigated Alzheimer’s disease and one 9 
investigated Dementia.  10 
The diagnosis requirement varied for each neurodegenerative disease; three 11 
of the four studies investigating participants from the Parkinson’s disease 12 
population required a diagnosis according to the UK PD Brain Bank criteria, 13 
and the other Parkinson’s disease study specified inclusion based on two 14 
questions that were designed by the authors of the study and a neurologist. 15 
Amyotrophic lateral sclerosis (ALS) was diagnosed according to El Escorial 16 
criteria, Alzheimer’s disease was diagnosed in accordance with National 17 
Institute of Neurological and Communicative Disorders and Stroke and the 18 
Alzheimer's Disease and Related Disorders Association (NINCDS-ARDA) 19 
(McKhann et al., 1984) criteria and Dementia was diagnosed according to the 20 
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) 21 
(American Psychiatric Association, 1994) criteria. 22 
4.2.2 Recruitment and intervention 23 




Participants were recruited from outpatient clinics, a hospital setting, care 1 
homes, social services, and the Parkinson’s disease community in a 2 
metropolitan city. One study did not state where they recruited participants 3 
from. 4 
The studies reported on five adapted third wave therapy interventions for 5 
people with neurodegenerative diseases; three studies adapted Mindfulness-6 
Based Stress Reduction (MBSR), one adapted both MBSR and Mindfulness 7 
Based Cognitive Therapy (MBCT), one used Mindfulness Based Alzheimer’s 8 
Stimulation (MBAS), one adapted Acceptance and Commitment Therapy 9 
(ACT) and one adapted mindfulness techniques but didn’t specify the 10 
mindfulness therapeutic approach. All studies offered group interventions that 11 
ran between one hour and two and a half hours, for a duration of between five 12 
weeks and two years.  13 
The interventions were facilitated by experienced mindfulness teachers, a 14 
clinical psychologist trained as a meditation practitioner, two trainee clinical 15 
psychologists trained in MBSR, the author of an adapted mindfulness model 16 
and professionals from psychology, physical therapy and psychiatry. One 17 
study did not state who facilitated the intervention.  18 
4.2.3 Control conditions 19 
In six studies participants in the control groups received treatment as usual 20 
which consisted of physical group therapy in patients with PD, regularly 21 
scheduled visits to a movement disorders specialist or neurologist, individual 22 
counselling and psychological support when requested. In one study, the 23 
treatment as usual patients were offered MBI two months after the study. 24 




Another study used a wait-list control group in which all participants eventually 1 
received the intervention, but only after the intervention group. 2 
Three studies specified that participants follow stable medication schedules for 3 
the duration of the study, one study stated that all participants in the 4 
intervention and control group used Donepezil; a drug that improves cognition 5 
and behaviour in people with Alzheimer’s disease. Three studies did not 6 
mention medication specifications.  7 
4.3 Results of studies (table 2) 8 
4.3.1 Anxiety 9 
Four studies investigated anxiety as an outcome through the use of four 10 
different measures (BAI, HADS, DASS 21 & RAIDS). The results were mixed, 11 
as two studies found that the control group scores for anxiety increased more 12 
than the intervention group (Ghielen et al., 2017; Pagnini et al., 2017) and two 13 
studies did not find a difference between the intervention and control group 14 
(Advocat et al., 2016Churcher Churcher Clarke, Chan, Stott, Royan & Spector, 15 
2017;). 16 
4.3.2 Depression 17 
Five studies investigated depression as an outcome through the use of four 18 
different measures (BDI, HADS, DASS 21 & CSDD). Mixed results were again 19 
found, with Ghielen et al., (2017) finding that depression increased in the 20 
intervention group more than in the control group at the three month follow up. 21 
Whereas, Pagnini et al., (2017) found that the control group experienced more 22 
of an increase in depression than the intervention group.  23 




Three studies either found a trivial effect size or did not find any difference 1 
between the intervention group and control group (Advocat et al., 2016; 2 
Churcher Clarke et al., 2017; Pickut et al., 2015). 3 
4.3.3 Quality of Life (QoL) 4 
Five studies investigated QoL as an outcome through the use of three different 5 
measures (ALSSQOL, PDQ-39, QoL-AD). The results were once again mixed, 6 
with Ghielen et al., (2017) finding, over three time points, that the control group 7 
had a poorer quality of life than the intervention group, in four subtests.  These 8 
subtests were, emotional wellbeing both at post intervention and at three 9 
month follow up, bodily discomfort at post intervention, and communication 10 
and activities of daily living at three month follow up.  However, the intervention 11 
group also had a poorer quality of life than the control group in three subtests; 12 
stigma at post intervention and bodily discomfort and mobility at three month 13 
follow up.  14 
Pagnini et al., (2017) and Churcher Clarke et al., (2017) found that the 15 
intervention group had a better quality of life than the control group. Whereas, 16 
Pickut et al., (2015) found that the intervention group experienced a poorer 17 
quality of life, on the pain subtest, than the control group. 18 
Advocat et al., (2016) did not find a difference between the intervention group 19 
and control group in the total quality of life score. 20 
4.3.4 Other outcomes – Stress, cognitive function, mindfulness and self-21 
efficacy 22 




Advocat et al., (2016) and Churcher Clarke et al., (2017) both found a small 1 
effect size, 0.32 and 0.28 respectively, that stress increased in the intervention 2 
group in comparison to the control group.  3 
Three studies (Churcher Clarke et al., 2017; Pickut et al., 2013; Quintana-4 
Hernandez et al., 2016) found improved cognitive functioning in the 5 
intervention group in comparison with the control group. The Churcher Clarke 6 
(2017) study found a small to medium effect size that suggests there was 7 
improved cognitive functioning in the intervention group. Also, the Pickut 8 
(2013) study found the intervention group showed significant changes in grey 9 
matter density in areas of the brain related to the pathophysiology of 10 
Parkinson’s disease following the intervention.  11 
Three studies looked at mindfulness and two found (Advocat et al., 2016; 12 
Pickut et al., 2015) an increase in mindfulness in the intervention group 13 
compared to the control group, with Advocat et al., (2016) identifying a medium 14 
effect size. However, Pagnini et al., (2017) did not find a difference in 15 
mindfulness between intervention and control groups over time. 16 
Ghielen et al., (2017) also investigated self-efficacy and found there was no 17 
difference between the groups at post intervention, but that the control group 18 
had a small effect size increase in self-efficacy compared to the intervention 19 
group at the three month follow up.  20 
4.4 Study quality 21 
The “Quality Assessment Tool for Quantitative Studies” (Effective Public 22 
Health Practice Project, 1998) identified that two studies were of a strong 23 
quality, whereas five studies were of a moderate quality. Four studies (Advocat 24 




et al., 2016; Churcher Clarke et al., 2016; Pickut et al., 2013; Quintana-1 
Hernandez et al., 2016) had a weak selection bias, and one study (Pagnini et 2 
al., 2017) had a weak withdrawal rate, as several participants were forced to 3 
withdraw from the study because their health deteriorated or died.  However, 4 
the withdrawal rate in the Pagnini (2017) study was forced due to death and 5 
illness. 6 
4.5 Measurement 7 
Where possible, Cohen’s d statistic for the difference between groups in terms 8 
of the change from pre-test to post-test was calculated. These effect sizes 9 
were calculated using the formula presented by Morris (2008). Some studies 10 
did not present effect sizes and it was therefore not possible to calculate them 11 
with the data presented in the papers. The studies that did present effect sizes 12 
provided a comparison between the mean of the intervention group and the 13 
mean of the control group, to see how they differ by their standard deviations. 14 
It is suggested that 0.2 is a small effect size, 0.5 is a medium effect size and 15 
0.8 is a large effect size.  16 
5.0 Discussion 17 
This narrative synthesis reviewed seven RCT studies for people with 18 
neurodegenerative diseases and found that third wave therapies, delivered in 19 
group settings, vary in their effectiveness in improving psychological wellbeing.  20 
Out of the RCT studies available for this review, the quality of two of the studies 21 
was found to be strong and five were found to be moderate. This identifies that 22 
the studies offered generally robust evidence, but more studies are required to 23 
identify the long term benefit of third wave therapies.  24 




Three studies found that the cognitive functioning outcome improved in the 1 
intervention group in comparison with the control group following third wave 2 
therapies. This is an interesting and potentially useful finding as it suggests 3 
that third wave therapies could assist in maintaining cognitive functioning, but 4 
one which requires further research. 5 
In most outcomes, mixed results were found in both the intervention and 6 
control groups. Findings identified that the third wave therapy interventions 7 
showed positive improvements in anxiety, depression, quality of life, and 8 
mindfulness. However, it was also found that the interventions caused 9 
negative outcomes such as an increase in depression, stress and a reduction 10 
in quality of life suggesting that further research is required.  11 
 Mindfulness Based Cognitive Therapy (MBCT) has been recommended by 12 
the NICE guidelines for chronic depression (NICE, 2009). In this review, only 13 
one study (Churcher Clarke et al., 2017) looked at an adapted mindfulness-14 
based cognitive therapy (MBCT) programme, finding a trivial effect size 15 
(d=0.06) for depression in the intervention group in comparison to the control 16 
group, following the treatment. Therefore, more research is required to assess 17 
whether MBCT reduces depression with a neurodegenerative disease 18 
population.  19 
It is potentially the case that the intensified bodily focus involved in third wave 20 
therapy practices increases awareness of the symptoms of bodily discomfort 21 
experienced by people with neurodegenerative disease. Thereby, leading to 22 
an increase in the intervention group of participants reporting such issues as 23 
decreased mobility quality of life and increased stress levels. 24 




However, this does not necessarily mean that the participants experienced an 1 
increase in their distress following third wave therapy, but potentially a better 2 
understanding and awareness of the already present neurodegenerative 3 
disease symptoms, which could potentially lead to a better awareness of their 4 
needs.  5 
There were five aims of the review:  6 
1) Examine the effectiveness of third wave therapies in improving outcomes in 7 
neurodegenerative diseases.  8 
Any RCT study that analysed the effectiveness of third wave therapies with a 9 
neurodegenerative disease population was reviewed. However, due to the low 10 
number of studies and the variety of neurodegenerative disease populations, 11 
third wave therapies and outcomes analysed in each of the studies, it was not 12 
possible to thoroughly examine the effectiveness of third wave therapies in 13 
improving outcomes in neurodegenerative diseases.  14 
2) Identify which third wave therapies have been used with which 15 
neurodegenerative disease diagnoses 16 
Mindfulness-based lifestyle program, body awareness training (BEWARE) 17 
based on the principles of ACT, Mindfulness Based Intervention (MBI) closely 18 
following Mindfulness Based Stress Reduction (MBSR), and Mindfulness 19 
Based Intervention (MBI) closely following Mindfulness Based Stress 20 
Reduction (MBSR) were all used with a PD population. Meditation training 21 
based on Mindfulness-Based Stress Reduction (MBSR) was used with the 22 
Amyotrophic Lateral Sclerosis (ALS) population. Mindfulness Based Stress 23 
Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) were 24 




used with a dementia population and Mindfulness Based Alzheimer’s 1 
Stimulation (MBAS) were used with an Alzheimer’s disease population.  2 
3) Identify which third wave therapy shows the most beneficial outcomes 3 
Again, because of the variability between studies, and limited number of RCT 4 
studies available, it is not possible to compare studies to clearly conclude that 5 
one third wave therapy shows the most beneficial outcomes.  6 
4) Assess the strength of the evidence for the benefit of third wave therapies 7 
for the neurodegenerative disease population 8 
The evidence that currently exists was assessed using narrative synthesis. It 9 
was concluded that the evidence is limited, as most of the studies looked at 10 
the Parkinson’s disease population, and there were fewer studies looking at 11 
other neurodegenerative diseases. As well as this, it was found that studies 12 
looked at a variety of third wave therapies, so this limits the ability to review 13 
the effectiveness of each therapy. It was also found that there is not a 14 
standardised way of adapting third wave therapies, so this again limits the 15 
strength of the evidence, as comparisons between studies cannot be made.  16 
5) Establish any weaknesses in the studies reviewed, and any potential future 17 
research recommendations.   18 
As previously mentioned, the review was limited because there was 19 
substantial variability between each of the studies, in their populations, the 20 
therapies analysed, the treatment available to the control groups and the 21 
outcome measures used. 22 




It is recommended for any potential future research to have a consensus on 1 
the measures that should be used when investigating the benefit of third wave 2 
therapies with this population. Therefore, consensus work should be done on 3 
appropriate outcomes for each diagnosis to allow for a clear comparison 4 
between studies. The Core Outcome Measures in Effectiveness Trials 5 
(COMET) (Prinsen et al., 2014) initiative have identified some outcomes for 6 
neurodegenerative diseases, but these have not been exclusively followed by 7 
the reviewed studies. 8 
As well as this, based on the findings in this study, it might be useful for future 9 
research to focus on only one neurodegenerative disease. From the studies 10 
that were reviewed, four out of the seven studies used a Parkinson’s disease 11 
population, so it might be beneficial for future studies to initially conduct 12 
research with this population to further improve the evidence base. Also, the 13 
findings in three of the studies, that cognitive functioning improves following 14 
third wave therapy in comparison to the control group, needs to be studied 15 
further and could be a focus of future research.   16 
5.1 Limitations  17 
As this is the first review of this population and third wave therapies, it has not 18 
been possible to focus more closely on just one specific third wave therapy or 19 
neurodegenerative disease, but such an approach will be beneficial in the 20 
future.  21 
The review was limited because there was substantial variability between each 22 
of the studies, in their populations, the therapies analyed, the treatment 23 
available to the control groups and the outcome measures used. 24 




The populations reviewed by the studies included four neurodegenerative 1 
diseases, of which, four studies investigated Parkinson’s disease, one 2 
investigated Amyotrophic Lateral Sclerosis (ALS), one investigated 3 
Alzheimer’s disease and one investigated Dementia. Therefore, because the 4 
development, progression and symptoms of each neurodegenerative disease 5 
are presented and experienced differently, it is difficult to make comparisons 6 
between each of these conditions. 7 
Similarly, the reviewed studies reported on five adapted third wave therapy 8 
interventions for people with neurodegenerative diseases; three studies 9 
adapted Mindfulness-Based Stress Reduction (MBSR), one adapted both 10 
MBSR and Mindfulness Based Cognitive Therapy (MBCT), one used 11 
Mindfulness Based Alzheimer’s Stimulation (MBAS), one adapted Acceptance 12 
and Commitment Therapy (ACT) and one adapted mindfulness techniques, 13 
but didn’t specify the mindfulness therapeutic approach. Once again, based on 14 
the differences between the therapies, and the lack of consistency in their 15 
adaptation to suit the neurodegenerative disease they were treating, it was not 16 
possible to confidently state which therapy was the most effective. 17 
As well as this, for the control groups, six of the studies offered treatment as 18 
usual which included a variety of physical group therapy, regularly scheduled 19 
visits to a movement disorders specialist or neurologist, individual counselling 20 
and psychological support when requested. In one study, the treatment as 21 
usual patients were offered MBI two months after the study. Another study 22 
used a wait-list control group in which all participants eventually received the 23 
intervention, but only after the intervention group. Therefore, there was 24 
substantial variability in the treatment offered to each control group, so it was 25 




not possible to isolate standard variables. This made it difficult to clearly 1 
determine whether third wave therapies or control groups were influencing 2 
change in outcomes, and therefore limited the ability to identify the 3 
effectiveness of each therapy. 4 
Finally, there were seven outcomes measured (e.g. anxiety, depression and 5 
quality of life) between the seven reviewed studies, with each study looking at 6 
a variety of these outcomes. Similar to the above mentioned limitations, this 7 
variety limited the comparisons that could be made between the studies, and 8 
therefore, restricted the interpretations and conclusions that could be made 9 
about the effectiveness of the third wave therapies.  10 
During the review search, several relevant studies that were in the process of 11 
being completed were found, and as such their final findings will likely improve 12 
the current knowledge base regarding the benefits of third wave therapies for 13 
the neurodegenerative disease population.  14 
5.2 Conclusions 15 
At this stage, due to the lack of RCT studies available, and the substantial 16 
variability between the RCT studies that were reviewed, it is not possible to 17 
deem whether third wave therapies are an effective treatment for the 18 
neurodegenerative disease population.  19 
Therefore, further research looking at third wave therapies and the 20 
neurodegenerative disease population is required. As well as this, it would be 21 
beneficial for third wave therapies to be adapted in a standardised way for this 22 
population. Research can then be replicated using the same standardised 23 




therapeutic approach, to measure whether change occurs in comparison to a 1 
control group.   2 
It would also be useful for future research to have a consensus on the outcome 3 
measures that should be used when investigating the effectiveness of third 4 
wave therapies with this population. Therefore, consensus work should be 5 
done on appropriate outcomes for each neurodegenerative disease, to allow 6 
for a clear comparison between studies7 




Table 1: Characteristics of the included studies 


































No. of p’pants: Total=72. Mindfulness= 35. 
Control=37. 
Age: Mindfulness group = 62.8 average, Control 
group=63.7 average.  
Gender: Mindfulness group= female 66.7%. 
Control group= female 51.5%.  
Inclusion criteria: 1) aged 18 to 70, 2) Fluent 
spoken and written English, 3) Able attend at least 
four sessions, 4) Community living adults with 
disability congruent H&Y Stage 2 PD.  
Mindfulness-based 
lifestyle program 
facilitated, two hour group 
sessions once a week for 
a total of 6-weeks. 
Two hour group sessions 
once a week for a total of 
6-weeks. 
Facilitator: Both the 
program facilitator and the 
author of the adapted 
mindfulness model. 
Wait-list 



























No. of p’pants: Total=31. Mindfulness=20 & 
control=11. 
Age: Total=80.61 average. Mindfulness=81.30, 
Control=79.36 average.  
Gender: Total=48% female. Mindfulness= 60% 
female. Control= 11%female. 
Adapted mindfulness 
programme guided by 
Mindfulness based stress 
reduction (MBSR) and 
mindfulness-based 
cognitive therapy (MBCT).  
TAU 




Cognitive status: Mild and moderate dementia. 
Inclusion criteria: 1) Dementia 2) mild to moderate 
cognitive impairment, 3) capacity to give consent, 
4) communicate verbally, 5) see and hear well 
enough to participate, 6) maintain concentration 
and remain in session, 7) speak English.  
Exclusion criteria: 1) had a major physical illness 
or disability that could impact participation, 2) had 
a diagnosis of learning disability, 3) were actively 
practising meditation or yoga or, 4) had a history 
of brain lesions or major head trauma. 
Ten one hour group 
sessions, running twice a 
week for 5 weeks. 
Facilitator: Two trainee 
clinical psychologists, 






















clinic in The 
Netherlands 
PD according 
to the UK PD 
Brain Bank 
criteria 
No. of p’pants: 19= Intervention, 19= treatment as 
usual. 
Age: ACT group= 59.6 average, control group= 
66.6,  
Gender: Intervention group = 35% female, control 
group = 45% female,  
Cognitive status: no cognitive impairment (mini 
mental state examination),  
Inclusion criteria: 1) idiopathic PD 2) one or more 
wearing-off symptoms, 3) clinically relevant 
anxiety.  
Exclusion criteria: 1) Cognitive impairment, 2) 
insufficient motivation for participation, 3) 
Body awareness training 
(BEWARE) based on the 
principles of ACT.  
12 sessions, 1-hour long, 
2 times per week for 6 
weeks 
Facilitator: Professionals 
from psychology, physical 
therapy and psychiatry.  
 
Treatment as 









neurological, orthopaedic or cardiopulmonary 
































No of p’pants: 50=MBSR group, 50=usual care 
group.  
Age: MBSR group = 57.9 average, usual care 
group = 63.4 average.  
Gender: MBSR group, female = 38%, usual care 
group, female = 34%. 
Cognitive status: No significant cognitive 
impairment.  
Inclusion criteria: 1) ALS, 2) 18 years or older, 3) 
ALS Functional Rating Scale Revised score above 
24, 4) ALS within 18 months, 5) ability to speak and 
understand.  
Exclusion criteria: 1) No secondary severe 
comorbidity, 2) significant cognitive and/or 
behavioural impairment, 3) history of psychiatric 
disorders. 
Meditation training based 
on the original 
Mindfulness-Based Stress 
Reduction (MBSR) 
programme and tailored 
for people with ALS. 
12 months study. 

























to the UK 
Brain Bank 
Criteria. 
No. of p’pants: Total=30, MBI=15, control 
group=15. 
Age: Total=61.8 average, MBI=61.4 average, 
Control=62.2 average.  
Mindfulness based 
intervention (MBI) closely 
following Mindfulness 
Based Stress reduction 
(MBSR).  















Gender: Total=48% female, MBI= 50% female, 
Control=46% female.  
Cognitive status: lack of cognitive dysfunction. 
Inclusion criteria: 1) PD, 2) Hoehn & Yahr stage I–
III, 3) lack of features suggestive of atypical 
parkinsonism, 4) exclusion of neuroleptics, 5) 
treated PD with medication and unlikely to be 
requiring anti-PD medication, 6) stable dose of all 
medications for 30 days, 7) lack of cognitive 
dysfunction, 8) no known unstable or life 
threatening disease, 9) no previous mindfulness 
training, 10) no contra indications for MRI 
scanning, 11) commitment to attend all eight MBI 
classes. 
2.5 hour meetings on eight 
consecutive weeks. 

















to the UK PD 
Brain Bank 
criteria. 
No. of p’pants: 14 =Intervention, 13 =usual care. 
Age: MBI= 61.4 average, usual care= 62.2 
average. 
Gender: MBI= 50% female, usual care= 46% 
female,  
Cognitive status:  lack of cognitive dysfunction,  
Inclusion criteria:1) PD, 2) Hoehn and Yahr stages 
I–III,3) lack of features suggestive of atypical 
parkinsonism,4) exclusion of neuroleptics,5) 
treated with PD medication and unlikely to require 
anti-PD medication,6) stable dose of medications 
Mindfulness based 
intervention (MBI) closely 
following mindfulness 
based stress reduction 
(MBSR). 
2.5 hours for 8 
consecutive weeks and 
home practice.  

















for 30 days prior, 7) lack of cognitive dysfunction,8) 
no known unstable or life threatening disease,9) no 
previous mindfulness training,10) commitment to 
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No of p’pants: 85, MBAS = 42, Control = 43. 
Age: All participants range = 65 - > 86 
Gender: total= 55% female. 
Cognitive status: Dementia diagnosis. 
Inclusion criteria: 1) AD, 2) dementia, 3) absence 
of other dementia diseases, 4) regional brain 
atrophy in volume loss of hippocampus, 5) 
entorhinal cortex or amygdala evidenced by MRI,6) 
early and significant episodic memory impairment 
including gradual and progressive change in 
memory function over six months, the episodic 
memory impairment can be isolated or associated 
with other cognitive change, 7) global deterioration 
scale 3, 4, or 5, living at home, 8) not attending 
other health service or using any other 
pharmacological treatment other than donepezil. 
Treatment 1: Mindfulness 
Based Alzheimer’s 
Stimulation (MBAS). 
Three weekly group 
sessions for 90 mins for 
two years. 
Facilitator:  Clinical 
psychologist with five 
years’ experience as 
meditation practitioner. 
TAU 






Table 2: Results – comparing psychological interventions vs control conditions 
Study Outcome 
measures 
Results – means (SD) Effect Size  Intervention vs 






1) FMI 9 
2) PDQ-394 
3a) DASS 21- 
Depression10 





Intervention mean (SD): 
1) FMI – Baseline: 37.1 (8.2), 7 week change (95 % CI): 4.88 (1.95 to 7.80), 6 month 
change (95 % CI): 0.95(−1.91 to 3.82). 
2) PDQ39 – Baseline: 22.2 (12.4), 7 week change (95 % CI): −0.54 (−3.41 to 2.32), 6 
month change (95 % CI): −0.89 (−3.71 to 1.93). 
3a) DASS-D – Baseline: 4.50 (5.22), 7 week change (95 % CI): 1.92 (0.201 to 3.63), 6 
month change (95 % CI): 0.78 (−0.90 to 2.47).  
3b) DASS-A – Baseline: 7.58 (4.79), 7 week change (95 % CI): 0.33 (−1.67 to 2.34), 6 
month change (95 % CI): −0.26 (−1.79 to 1.27).  
3c) DASS-S – Baseline: 8.78 (6.35), 7 week change (95 % CI): 2.17 (0.12 to 4.23), 6 
month change (95 % CI): −1.0 (−2.89 to 0.89).  
 
Control mean (SD): 
1) FMI – Baseline: 34.5 (8.8), 7 week change (95 % CI): −1.06 (−3.81 to 1.68). 
2) PDQ39 – Baseline: 26.8 (17.5), 7 week change (95 % CI): −1.53 (−3.64 to 0.57). 
7 week effects change 
comparison between groups: 
1) FMI:  0.61 
2) PDQ39: 0.06 
3a) DASS-D: 0.12 
3b) DASS-A: 0.14 
3c) DASS-S: 0.32 
 
 
Moderate - TAU group received 
the intervention 
after the 7-week 
measures were 
collected for the 
intervention group. 
Therefore, for the 6 
months scores, all 
participants 
completed 
intervention.   
 
 




3a) DASS-D – Baseline: 7.19 (7.83), 7 week change (95 % CI): 1.06 (−0.84 to 2.97). 
3b) DASS-A – Baseline: 9.81 (7.56), 7 week change (95 % CI): −0.63 (−2.92 to 1.67). 




1) CSDD 11 
2) RAIDS 12 
3) QoL-AD 13 
4) MMSE 14 
5) PSS-13 15 
 
Intervention Mean (SD):  
1) CSDD- Baseline: 6.80 (4.35) and post 5.75 (4.05)  
2) RAIDS - Baseline: 7.80 (5.63) and post: 5.50 (3.94).  
3) QoL-AD- Baseline: 34.02 (4.24) and post 36.37 (4.27).  
4) MMSE- Baseline: 15.85 (3.68) and post: 15.25 (4.35).  
5) PSS-13 – Baseline: 20.33 (7.12) and post: 23.89 (7.59)  
 
Control mean (SD): 
1) CSDD- Baseline: 7.88 (6.90) and post:  5.25 (4.62)      
2) RAIDS - Baseline: 8.25 (5.52) and post: 5.88 (5.33)     
3) QoL-AD- Baseline: 34.58 (4.69) and post: 32.79 (4.44)      
4) MMSE- Baseline: 15.75 (4.27) and post: 13.50 (6.14)       
5) PSS-13-– Baseline:  22.50 (4.66) and post: 23.50 (4.04)  
 
1) CSDD: 0.06,  
2) RAIDS: 0.04,  
3) QoL-AD: 0.82,  
4) MMSE: 0.45,  






1) BDI 1 
2) BAI 2 
3) GSES 3 
4a) PDQ 39 - 
mobility 4 
4b) PDQ 39 - 
activities of 
daily living 4 
Intervention Mean & SD:  
1) BDI – Baseline: 9.80 (7.63), post: 9.07 (6.01), follow-up: 10.47 (7.76).  
2) BAI – Baseline: 40.47 (13.71) post: 35.69 (12.14) follow-up: 36.67 (9.85).  
3) GSES – Baseline: 30.75 (5.70), post: 30.93 (3.56), follow-up: 31.57 (7.00).  
4a) PDQ 39 mobility - Baseline: 38.55 (19.58), post: 37.50 (21.13), follow-up: 40.67 
(21.35). 
4b) PDQ 39 activities - Baseline: 36.57 (18.22), post: 32.78 (19.21), follow-up: 32.14 
(19.30). 
1) BDI – post: -0.11, follow-
up: 0.39. 
2) BAI – post: -0.42, follow-
up: -0.12. 
3) GSES – post: 0.02, follow-
up: -0.27. 
4a) Mobility – post: -0.08, 
follow-up: -0.28.  
Strong  




4c) PDQ 39 -
emotional 
wellbeing 4 
4d) PDQ 39 -
stigma 4 
4e) PDQ 39 -
social support4 
4f) PDQ 39 –
cognitions 4 














4c) PDQ 39 emotional - Baseline: 32.02 (19.89), post: 26.94 (19.15), follow-up: 21.73 
(19.35). 
4d) PDQ 39 stigma - Baseline: 22.06 (18.89), post:  22.92 (21.48), follow-up: 19.17 
(22.34). 
4e) PDQ 39 social - Baseline: 24.48 (18.63), post: 21.11 (21.33), follow-up: 22.22 
(18.00). 
4f) PDQ 39 cognitions - Baseline: 34.38 (17.18), post: 33.33 (16.65), follow-up: 34.17 
(17.66). 
4g) PDQ 39 communication - Baseline: 27.19 (15.43), post: 26.67 (19.21), follow-up: 
25.00 (16.96). 




Control Mean & SD: 
1) BDI – Baseline: 12.30 (8.39), post: 12.44 (5.41), follow-up:  9.81 (8.52).     
2) BAI – Baseline: 39.05 (9.23), post: 39.25 (9.43), follow-up: 36.69 (6.05).            
3) GSES – Baseline: 28.50 (4.56), post: 28.56 (4.27), follow-up: 30.75 (4.78).   
4a) PDQ 39 mobility - Baseline: 48.55 (19.01), post: 45.78 (18.18), follow-up: 45.00 
(21.95). 
4b) PDQ 39 activities - Baseline: 33.99 (17.14), post: 33.59 (20.44), follow-up: 34.64 
(24.33). 
4c) PDQ 39 emotional - Baseline: 40.28 (21.10), post: 40.10 (17.93), follow-up: 35.16 
(15.95). 
4d) PDQ 39 stigma - Baseline: 30.00 (16.91), post: 26.17 (20.18), follow-up: 30.08 
(19.53). 
4b) Activities – post: -0.18, 
follow-up: 0.28. 
4c) Emotional – post: 0.23, 
follow-up: 0.24. 
4d) Stigma - post: -0.25, 
follow-up: 0.16. 
4e) Social - post: 0.07, follow-
up: 0.03. 
4f) Cognitions - post: 0.09, 
follow-up: 0.17. 
4g) Communication - post: -
0.01, follow-up: 0.34.  
4h) Discomfort - post: 0.41, 
follow-up: -0.28. 




4e) PDQ 39 social - Baseline: 25.42 (18.82), post: 23.44 (17.80), follow-up: 23.81 
(18.74). 
4f) PDQ 39 cognitions - Baseline: 33.44 (17.36), post: 33.98 (17.53), follow-up: 36.33 
(17.71). 
4g) PDQ 39 communication - Baseline: 32.50 (22.28), post: 31.77 (19.77), follow-up: 
36.98 (19.24). 







1c) People and 
environment 7 
1d) Intimacy 7 
1e) Religiosity 
7 
1f) Physical 7 
1g) Bulbar 7 




3) FFMQ 6 
 
Intervention mean & SD: 
1a) ALSSQOL (single-item scale) – Baseline: 5.77 (1.95)      
1b) Negative emotion – Baseline: 5.93 (1.50)       
1c) People and environment – Baseline: 7.33 (1.63)       
1d) Intimacy – Baseline: 5.65 (2.17)        
1e) Religiosity – Baseline:  5.42 (2.91)        
1f) Physical – Baseline: 6.25 (2.15)  
1g) Bulbar – Baseline: 6.77 (2.73)    
2a) Anxiety – Baseline: 7.84 (3.22)     
2b) Depression – Baseline: 5.86 (2.77)     
3) FFMQ – Baseline:  3.62 (0.42)     
 
Control mean & SD: 
1a) ALSSQOL (single-item scale) – Baseline: 5.77 (2.36) 
1b) Negative emotion – Baseline: 5.70 (1.54) 
1c) People and environment – Baseline: 7.34 (1.41) 
1d) Intimacy – Baseline: 5.14 (1.74) 
1e) Religiosity – Baseline: 5.37 (3.59) 
No follow up scores are 
available, so effect sizes 
could not be calculated. 
 
Analyses indicate that control 
group experience increasing 
anxiety and depression and 
decreasing quality of life over 
time. The intervention 










1f) Physical – Baseline: 6.08 (1.91) 
1g) Bulbar – Baseline: 6.12 (2.47) 
2a) Anxiety – Baseline: 7.24 (3.66) 
2b) Depression – Baseline: 6.36 (2.84) 







a 3 Tesla 
scanner 
“MRI findings showed increased grey matter density (GMD) in the intervention 
group compared to the control group overtime in the left and right hippocampus 
and a small region in the right amygdala”. 
 
However, “increased GMD was found in the control compared to the intervention 
group in the anterior lobe and dentate nucleus of the left cerebellum”.  
 
Therefore, the study found the intervention group showed significant changes in 
GMD in areas of the brain related to the pathophysiology of Parkinson’s disease, 
after eight weeks of mindfulness.  
 
No mean and standard 
deviations available so effect 
sizes could not be calculated. 










1) UPDRS 5  
2) FFMQ 6 
3) PDQ-39 4 
 
Intervention Mean:  
1) UPDRS motor III score - Baseline: 27.43, post: 21.93.  
2) FFMQ observe facet - Baseline: 24.14, post: 27.29. 
3) PDQ-39- pain score - Baseline: approx. 7.5, post: approx. 8.3 
 
Control Mean:  
1) UPDRS motor III score – Baseline: 27.92, post: 29. 
2) FFMQ observe facet – Baseline: 23.69, post: 23.54.  
3) PDQ-39- pain score – Baseline: approx. 8.0, post: approx. 7.3.  
No standard deviations are 
available so effect sizes could 




control in 3 outcome 
scores.  
-The mean and SD 
for BDI and other 
UPDRS, FFMQ and 
PDQ 39 subscales 
and total scores, 




were not provided as 







1) MMSE 14 
2) CAMCOG 16 
Mild-moderate AD intervention group mean (SD) 
1) MMSE - Baseline: 22.46(2.8), 6 months: 22.31(3.18), 12 months: 21.49 (3.46), 18 
months: 21.66(3.34), 24 months: 20.86 (3.81). 
2) CAMCOG - Baseline: 71.40(9.80), 6 months: 72.46(10.73), 12 months: 
71.17(11.70), 18 months: 71.20(11.97), 24 months: 68.49(14.50). 
 
Mild-moderate AD control group mean (SD) 
1) MMSE - Baseline: 21.60(2.42), 6 months: 19.80(3.57), 12 months: 18.12(3.90), 18 
months: 15.56(5.15), 24 months: 14.12(5.11). 
2) CAMCOG - Baseline: 66.84(7.93), 6 months: 60.12(10.03), 12 months: 
52.08(15.53), 18 months: 48.76(16.35), 24 months: 41.32(17.17). 
 
Moderate-severe AD intervention group mean (SD) 
1) MMSE - Baseline: 17.00(0.89), 6 months: 20.33(2.08), 12 months: 21.00(2.64), 18 
months: 20.33(3.21), 24 months: 18.00(1.73). 
2) CAMCOG - Baseline: 64.67(8.08), 6 months: 62.00(4.58), 12 months: 64.67(6.11), 
18 months: 66.00(7.81), 24 months: 57.33(8.74).  
Moderate-severe AD control group mean (SD) 
1) MMSE - Baseline: 16.00(0.93), 6 months: 16.38(4.47), 12 months: 16.38(3.93), 18 
months: 14.38(7.89), 24 months: 11.29(5.25). 
2) CAMCOG - Baseline: 50.63(5.32), 6 months: 50.13 (10.97), 12 months: 
50.88(12.14), 18 months: 36.13(20.07), 24 months: 30.29(17.25).  
The sample sizes for the mild- 
moderate intervention and 
control groups, and the 
moderate-severe 
intervention and control 
groups were not displayed. 
Therefore, the effect sizes for 
each group could not be 
calculated.  
Moderate  





1) BDI= Beck Depression Inventory, 2) BAI= Beck Anxiety Inventory, 3) GSES =General Self-Efficacy Scale, 4) PDQ-39 = The Parkinson's Disease Questionnaire-39 5) 
UPDRS=Unified Parkinson’s Disease Rating Scale, 6) FFMQ=Five Facet Mindfulness Questionnaire, 7) ALSSQOL-R=ALS-Specific Quality of Life Revised scale, 8) HADS= 
Hospital Anxiety and Depression Scale, 9) FMI=Freiburg Mindfulness Inventory, 10) DASS 21 = Depression Anxiety Stress Scales, 11) CSDD= Cornell Scale for Depression in 
Dementia, 12) RAIDS=Rating Anxiety in Dementia Scale, 13) QOL-AD= Quality of Life Alzheimer’s Disease scale, 14) MMSE=Mini-Mental State Examination, 15) PSS-13= 
Perceived Stress Scale, 16) CAMCOG= Cambridge Cognition Examination 
Effect sizes calculated using Cohen’s d. It is suggested that 0.2 is a small effect size, 0.5 is a medium effect size and 0.8 is a large effect size. 
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1.0 Abstract 1 
Background/aims: The role of psychological factors in the development and 2 
progression of Inflammatory Bowel Disease (IBD) is not completely 3 
understood. Several studies have suggested that defence styles, alexithymia 4 
and illness perceptions each individually influence the way a person 5 
experiences their disease, thereby impacting on health related quality of life 6 
(HRQoL). The study aimed to expand the knowledge base and assist in 7 
offering a better understanding of these variables.  8 
Methods: The study employed a survey design and used opportunity sampling 9 
to recruit participants with IBD from a Regional Crohn’s and Colitis support 10 
group and outpatient Gastroenterology clinics. Participants were given 11 
questionnaire packs containing measures and were asked to post them back 12 
to the researcher. 13 
One hundred and thirty-nine participants were included in the study, of these 14 
73.5% were female and 26.5% were males. 53.6% of participants reported 15 
being diagnosed with Crohn’s disease, where as 41.3% were diagnosed with 16 
Ulcerative Colitis, 1.4% were diagnosed with both, and 3.6% had a diagnosis 17 
of IBD but did not have a clear diagnosis of either Crohn’s or Colitis. The 18 
majority of participants identified that they were diagnosed with IBD between 19 
the ages of 20 and 29. Most participants (60.4%) felt that stress and worry was 20 
the cause of their IBD.  21 
Results: The study found that defence styles, alexithymia and illness 22 
perceptions were all correlated with HRQoL. However, multiple regression 23 
analysis revealed that the alexithymia subtest, “difficulty identifying feelings” 24 




and the neurotic defence style were the only variables that had a significant 1 
relationship with HRQoL. It was also found that females and people that were 2 
recently diagnosed also had a worse HRQoL. 3 
Conclusion: These findings suggest that females who are recently diagnosed 4 
with IBD and have difficulty identifying feelings as well as a reliance on neurotic 5 
defence styles have a worse HRQoL. Therefore, screening of this population 6 
and the introduction of psychotherapy to assist with emotional care might be 7 
beneficial in improving HRQoL. 8 
Practitioner Points 9 
+ Gender, time since diagnosis, neurotic defence styles and difficulties 10 
identifying own emotional experiences found to potentially contribute to poorer 11 
HRQoL. 12 
+ Therefore, therapy using emotional identification, especially when a person 13 
is just diagnosed, might be beneficial to people with IBD.  14 
- The study used a cross sectional design, therefore it is not possible to infer 15 











2.0. Introduction 1 
2.1 Inflammatory Bowel Disease (IBD) 2 
Inflammatory Bowel Disease (IBD) is an umbrella term used to describe a 3 
chronic inflammation of the digestive system, large intestine and the rectum. 4 
The most commonly diagnosed illnesses under the IBD umbrella are 5 
Ulcerative Colitis and Crohn's disease (Mawdsley and Rampton, 2006). 6 
Approximately, three hundred thousand people in the UK and three million 7 
people in Europe are currently diagnosed with IBD (Burisch, Jess, Martinato, 8 
& Lakatos, 2013). 9 
IBD symptoms can be both physical (e.g. bloody diarrhoea, joint pain, and 10 
fever) and psychological (e.g. stress, anxiety and depression) (Neuendorf, 11 
Harding, Stello, Hanes, & Wahbeh, 2016; Sajadinejad, Asgari, Molavi, 12 
Kalantari, & Adibi, 2012). Due to both the physical and psychological 13 
symptoms, it is estimated that IBD costs society and the health care systems 14 
in Europe between 4.6 and 5.6 billion Euros per year (Burisch et al., 2013).  15 
However, to date, emotional support for psychological symptoms has been 16 
limited, as psychoactive drugs are offered at a much higher rate than 17 
psychotherapy, despite psychotherapies, such as third wave therapy, being 18 
widely requested and shown to be effective for people with IBD (Tarricone et 19 
al., 2017). As such, recent research has focused on further understanding the 20 
psychological factors involved in managing the disease, with the hope of 21 
improving health related quality of life and reducing the economic burden. A 22 
recent systematic literature review of the psychological correlates in IBD found 23 
an association with neurotic defence styles, illness perceptions and 24 




alexithymia with negative adjustment outcomes, namely quality of life (Jordan 1 
Sin, Fear, & Chalder, 2016). 2 
2.2 Illness perceptions  3 
A person’s illness perceptions are influenced by their personal experiences 4 
and the information they hold about the illness, such as personal identity, the 5 
cause, the consequence and the curability of the illness (Leventhal, Nerenz, & 6 
Steele, 1984).  7 
Previous studies have identified that illness perceptions can vary in people with 8 
IBD. Mussell, Böcker, Nagel, & Singer (2004) found that people with IBD tend 9 
to have illness perceptions that are either associated with responsibility for the 10 
outcome of the illness to themselves, others or fate. Other findings have 11 
identified that negative illness perceptions relating to social defamation and 12 
rejection, the social limits placed on a person due to the symptoms, and the 13 
concern of serious consequences, are related to poor HRQoL outcomes. As 14 
well as this, it was found that the perception of stigma felt by people with IBD 15 
can contribute to between 10 - 22% variance of their reported HRQoL (Dorrian, 16 
Dempster, & Adair, 2008; Faust, Halpern, Danoff-Burg & Cross, 2012; Kiebles, 17 
Doerfler & Keefer, 2010; Taft, Keefer, Leonhard & Nealon‐Woods, 2009).   18 
It has also been found that being positive about the ability to manage and care 19 
for personal symptoms is related to an increase in HRQoL in people with IBD 20 
(Munson, Wallston, Dittus, Speroff, & Roumie, 2009). This suggests that 21 
improving illness perceptions, can also improve HRQoL. However, to improve 22 
illness perceptions, a person’s emotional protective processes must also be 23 
able to cope with the impact of the illness.  24 




2.3 Defence styles 1 
Studies on the role of defence styles in determining HRQoL within IBD 2 
populations have been limited; however, they suggest that certain defence 3 
profiles can have an impact. Hyphantis et al., (2010) found a significant positive 4 
correlation between IBD and immature defence profiles, namely maladaptive 5 
action and displacement. These defence styles are regarded as being socially 6 
undesirable, such as being passive aggressive, somatisation and retreating 7 
into fantasy. In particular, Hyphantis et al., (2005) demonstrated that Crohn’s 8 
disease patients demonstrated higher levels of immature defence styles when 9 
compared to individuals with Ulcerative colitis.  10 
Also, high rates of the immature defence style somatisation, which is a physical 11 
manifestation of emotional discomfort, is associated with a deprived HRQoL in 12 
people with IBD (Hyphantis et al., 2010). Whereas in contrast, IBD patients 13 
who adopted mature defence styles had lower relapse rates and surgical 14 
interventions.  The mature defence styles, such as humility, mindfulness and 15 
forgiveness, are regarded as those that are displayed by emotionally healthy 16 
individuals.  17 
Other studies have identified neurotic defence styles, which are regarded as 18 
being acceptable defences in the short term but not in the long term (e.g. 19 
repression, isolation and reaction formation), as being associated with poorer 20 
HRQoL of people with IBD (Barbera et al., 2017; Moreno-Jimenez et al 2007;). 21 
Interestingly, the neurotic defence style, reaction formation, which is to behave 22 
in a way that is the opposite of how a person wants or needs to behave, has 23 




been independently associated with a poor HRQOL in people with IBD 1 
(Hyphantis, Tomensen, Bai & Creed, 2009).  2 
Therefore, it is potentially the case that people with IBD struggle to manage 3 
the negative illness perceptions and emotions associated with their illness, 4 
such as stigma, rejection and shame. As a result, unhealthy defence styles are 5 
adopted that offer protection from acknowledgment and resolution of these 6 
negative emotions (Freud 1936; Vaillant, 1992).    7 
 2.4 Alexithymia 8 
The potential reason that some people with IBD struggle to manage their 9 
negative emotions, is because they have difficulty identifying and describing 10 
them.  11 
Alexithymia can be translated from Greek, to mean “without words for 12 
emotions” (Sifneos, 1996).  It describes a person that is incapable of 13 
understanding or recognising their own feelings (Sifneos, 1996). Nemiah & 14 
Sifneos (1970) described patients that they believed had alexithymia as 15 
“seemingly detached, unconcerned, and distant”.  Alexithymia has been found 16 
to be prevalent at a rate of between 5 -13% in the general population (Taylor, 17 
Bagby & Parker, 1997). However, it has been found to be prevalent at a higher 18 
rate in people with IBD (Iglesias-Rey et al, 2012; Moreno-Jiménez et al, 2007; 19 
Porcelli, Taylor, Bagby & De Carne, 1999).   20 
Recent research has identified that alexithymia, along with defence styles, are 21 
related to severe physical conditions in females with IBD (Barbera et al, 2017). 22 
This finding is supported by previous research which suggests that 23 
alexithymia, specifically the subtests, “Difficulty identifying feelings” and 24 




“externally oriented thinking” are associated with a low HRQoL in people 1 
with IBD (Iglesias-Rey et al., 2012). It has also been found that having a 2 
greater difficulty describing feelings is linked to a poorer HRQoL (Moreno – 3 
Jimenez, Blanco, Rodríguez-Muñoz & Hernández, 2007). As well as this, it has 4 
been suggested, that along with distress, alexithymia might have a significant 5 
effect on the symptomology of IBD (Filipovic & Filipovic, 2014).    6 
It has been argued that the association might be explained by the difficulty that 7 
people with alexithymia have in recognising and regulating their own emotions. 8 
This inability to resolve the discomfort then manifests itself physically, which 9 
may be attributed to the IBD symptomology, and further contributes to a 10 
reduced HRQoL (Porcelli, Leoci, Guerra, Taylor, & Bagby, 1996; Porcelli, 11 
Zaka, Leoci, Centonze, & Taylor, 1995; Verissimo, Mota-Cardoso, & Taylor, 12 
1998).   13 
2.5 Rationale 14 
Recent research has found that defence styles, specifically the neurotic 15 
defence style, alexithymia subtests, and illness perceptions are related to 16 
HRQoL in the IBD population regardless of disease activity. However, to date 17 
no studies have collectively looked at the variables to identify the extent of their 18 
relationship with HRQoL and which of these psychological variables is most 19 
strongly related to HRQoL in this context.  20 
The findings will expand the knowledge base and assist in offering a better 21 
understanding of the variables that influence the HRQoL of people with IBD. 22 
The practical clinical benefit of the study is that it will assist in producing 23 




empirical evidence that will inform future psychological interventions by 1 
assisting in identifying key variables.  2 
2.6 Research question 3 
What is the extent of the relationship between the predictor variables, defence 4 




















3.0 Method 1 
3.1 Participants  2 
The study used opportunity sampling to recruit participants from an IBD charity 3 
and outpatient Gastroenterology clinic. 4 
Inclusion criteria included both male and female participants from the age of 5 
18 years old who had the ability to give consent and had sufficient English 6 
language comprehension to understand and complete the questionnaires. 7 
The participants had a diagnosis of Inflammatory Bowel Disease. The 8 
diagnosis and type of IBD was identified by participants on the demographic 9 
self-report form.  10 
A sample size of 129 is sufficient to detect an R-squared value of at least 11 
0.17 in a regression model with 14 predictors, with 90% power, using an 12 
alpha value of 0.05. As the regression model in this paper has an R-squared 13 
value of 0.45, the analysis has sufficient power. 14 
3.2 Materials 15 
3.2.1 Demographic self-report form (Appendix A) 16 
The self-report form consisted of demographic and illness related information. 17 
It asked about gender, age, diagnosis, years since diagnosis and co-morbidity.  18 
The form attempted to capture any potential confounding variables. 19 
Confidentiality of data was ensured as personal details had not been 20 
requested from the participants. 21 




3.2.2 Toronto Alexithymia Scale - TAS-20 (Bagby, Parker, & Taylor, 1994; 1 
Taylor, Bagby, & Parker, 1997)  2 
The TAS - 20 is a 20 item self-report questionnaire of alexithymia. The 3 
measure consists of 3 sub-scales which include: difficulty identifying feelings, 4 
difficulty describing feelings, and an externally orientated thinking style. A 5 
score from 51 to 61 on the measure identifies “possible alexithymia”, where as 6 
a score above 61 suggests that a person has alexithymia. The TAS 20 has 7 
both a high test-retest reliability and internal reliability (Bagby, Parker & Taylor 8 
1994; Bagby, Taylor & Parker, 1994). 9 
3.2.3 The Brief Illness Perceptions Questionnaire -BIPQ (Moss-Morris, 10 
Weinman, Petrie, et al, 2002;  Broadbent, Petrie , Main & Weinman, 2005)  11 
The BIPQ is an eight item scale measure of illness perception that measures 12 
cognitive and emotional representation of illness perceptions. There is also a 13 
ninth item that allows for a qualitative response to be given.  14 
The measure consists of an 11 point likert scale (0-10). It is designed to be 15 
prompt, valid and effective in large scale studies. The questionnaire can either 16 
produce a total overall score or it can produce sub scale scores (Karataş, Özen 17 
& Kutlutürkan, 2017). However, there is no standardised way of identifying the 18 
sub scale groups. The measure has good test-retest reliability and validity with 19 
relevant measures (Broadbent, Petrie, Main & Weinman, 2006). 20 
 21 
 22 
3.2.3.1 BIPQ Subscales 23 




Subscales have been suggested for the BIPQ, but the psychometric properties 1 
of these subscales have not been evidenced. Therefore, principal components 2 
analysis was conducted to determine whether any subscales are likely to exist 3 
within this sample. The analysis identified two components of the BIPQ; these 4 
were named “consequence focused” (i.e. questions 1-4) and “illness focused” 5 
(i.e. questions 5-8). 6 
 7 
Questions in the “consequence focused” component (e.g. “How much does 8 
your illness affect your life?”) were closely related to the IBDQ outcome 9 
questions (e.g. “How often in the past 2 weeks have you had to delay or cancel 10 
a social engagement/ felt generally unwell/ tired and worn out/ unable to attend 11 
school or work/?”) and were therefore removed from analysis due to overlap. 12 
The “illness focused” component questioned a person’s perception of their 13 
illness (e.g. “How concerned are you about your illness?”) and was included in 14 
the analysis. Therefore, from here on all analysis excluded the “consequence 15 
focused” component of the BIPQ. A higher score on the illness focused sub-16 
scale represents a more threatening perception of the illness.  17 
 18 
3.2.4 Defense Style Questionnaire – DSQ-28 (Andrews, Singh, & Bond, 1993)  19 
The Defense Style Questionnaire (DSQ-28) is a shortened version of the DSQ-20 
40. The DSQ-40 was lacking in face validity and internal consistency on 21 
several items, so these items were removed and the DSQ-28 was created. It 22 
is a 28 item questionnaire with a 9 point likert scale ranging from “disagree 23 
strongly” to “strongly agree”. It assesses mature, neurotic and immature 24 
defence styles. With the removal of the items from DSQ-40, the measure was 25 




found to have improved discriminant and criterion validity (Saint Martin, Valls, 1 
Rousseau, Callahan, & Chabrol, 2013). 2 
3.2.5 Inflammatory Bowel Disease Questionnaire - IBDQ (Irvine, Zhou, & 3 
Thompson, 1996)  4 
The IBDQ is a 32 item self-administered or interview administered measure of 5 
the health related quality of life (HRQOL) of people with IBD. The measure 6 
consists of four differing domains which include; bowel symptoms, emotional 7 
health, systemic systems and social function. The questionnaire produces 8 
scores on a range between 1-7, with 1 representing a poor HRQOL and 7 9 
representing a good HRQOL. The IBDQ is a widely used instrument that has 10 
demonstrated its reliability and validity cross-culturally (Han, McColl, Steen, 11 
Barton, & Welfare, 1998; Pallis, Mouzas & Vlachonikolis, 2004).   12 
3.3 Design and Statistical Analysis 13 
The study employed a cross –sectional survey design. Exploratory analysis of 14 
the data identified that the variables met the required assumptions of normality 15 
and linearity for statistical analysis. Pearson product-moment correlation 16 
coefficient (r) was conducted to identify the strength of the relationship 17 
between the independent variables (defence styles, alexithymia and illness 18 
perceptions), and the dependent variable; health related quality of life.  19 
Also, a multiple regression analysis was conducted to determine the amount 20 
of variance in HRQoL that is explained by the independent variables.  21 
3.4 Procedure 22 




Information and invitation sheets were displayed on the IBD charity website 1 
and in the newsletter (See appendix B). Questionnaire packs were then 2 
posted out to members of the IBD charity by the charity organisers to ensure 3 
confidentiality. Posters were also put up in the outpatient Gastroenterology 4 
clinic and a nurse gave out the application packs when requested by 5 
interested potential participants.  6 
The questionnaire pack which contained the information sheet, one 7 
demographic self-report form and four questionnaires were returned by post, 8 
using the stamped addressed envelope, to the University, Psychology 9 
Department.  10 
520 questionnaire packs were given out to participants, 420 through the IBD 11 
charity and 100 through the Gastroenterology clinic. 145 questionnaire packs 12 
were returned and 139 were eligible and used in the study. 13 
The study was granted ethical approval by the NHS Research Ethics 14 







4.0 Results 22 




The relationship between the predictor variables, defence styles, illness 1 
perceptions and alexithymia subtests, with the outcome variable, HRQoL 2 
were measured using a correlation and multiple regression analysis.  3 
4.1 Demographics  4 
One hundred and thirty-nine participant questionnaire packs were included in 5 
the study. The majority of participants were female, with 73.5% of responses 6 
compared to 26.5% of males. Participants were most commonly aged 7 
between 30 and 49 years old and most people identified that they were 8 
diagnosed with the disease between the ages of 20 and 29. Crohn’s Disease 9 
was the most common type of IBD identified, and 57% stated that they also 10 
had another medical condition. Most participants (60.4%) felt that stress and 11 
worry was the cause of their IBD (see table 1). 12 
4.2 Measures 13 
The illness focused perceptions mean score was found to be similar to other 14 
IBD population studies (Knowles, Cook, & Tribbick, 2013; Knowles, Gass, & 15 
Macrae, 2013). The Alexithymia mean score was found to be higher than the 16 
general population and other studies investigating IBD populations, suggesting 17 
higher levels of alexithymia (Barbera et al., 2017; Franz et al., 2007). For 18 
defence styles, the immature defence style was the most common response, 19 
similar to previous studies (Hyphantis et al., 2005). The HRQoL total score was 20 
found to be lower than in other IBD studies (Han et al., 1998; Pallis, 21 
Vlachonikolis & Mouzas, 2002), but higher than other findings (De Boer, 22 
Wijker, Bartelsman, & de Haes, 1995), suggesting a low quality of life (see 23 
table 2).  24 




4.3 Correlation 1 
A series of correlations were performed to examine the relationship between 2 
the predictor variables, defence styles, illness perceptions and alexithymia 3 
subtests, with the outcome variable, HRQoL. A significant relationship was 4 
found between each of the variables and HRQoL. The alexithymia subscale, 5 
“difficulty identifying feelings”, had the strongest association, with a strong, 6 
negative and significant relationship with HRQoL (r = -0.54, p <0.001) (see 7 
table 3).  8 
4.4 Multiple regression analysis 9 
Multiple regression analysis was conducted to examine the relative strength of 10 
the relationship between demographic information, alexithymia, defence styles 11 
and illness perceptions (the covariates) with HRQoL (the outcome measure). 12 
A significant regression equation was found (F(14, 114) =  6.687, p=.000), with 13 
an R2 of .451.   14 
Overall, time since diagnosis (beta = 0.22, p= 0.018), gender (beta = 0.20, p= 15 
0.009), difficulty identifying feelings (beta = -0.33, p= 0.003) and neurotic 16 
defence style (beta = -0.18, p= 0.041) were all statistically significant 17 
measures for explaining variance in HRQOL. Difficulty identifying feelings 18 
recorded the highest significant beta value out of all the contributors thereby 19 
identifying that it made the strongest unique contribution to explaining the 20 
total IBD HRQOL score. A total of 45.1% variance of HRQoL was explained 21 
by the model (see table 4). 22 
5.0 Discussion  23 
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This study examined the extent that defence styles (mature, immature and 1 
neurotic), alexithymia subtests (difficulty identifying feelings, difficulty 2 
describing feelings and externally orientated thinking) and illness perceptions, 3 
are related to HRQoL in IBD.  4 
It was found that all of the variables were significantly correlated to HRQoL. 5 
However, in the multiple regression analysis, only the alexithymia subtest, 6 
“difficulty identifying feelings” and the neurotic defence style had a significant 7 
relationship with HRQoL. From the demographic information, gender and time 8 
since diagnosis, were also both significantly related with HRQoL, suggesting 9 
that females and participants more recently diagnosed with IBD, have a worse 10 
HRQoL.  11 
These findings are similar to those found in recent research which identifies 12 
that alexithymia, along with the neurotic defence style, are related to severe 13 
physical conditions in females with IBD (Barbera et al., 2017). In the study, it 14 
was suggested that females with alexithymia are more likely to develop IBD 15 
than males because females somaticize their emotional pain, whereas males 16 
with alexithymia develop behavioural issues. It has also been suggested that 17 
such difficulties associated with alexithymia might have a significant effect on 18 
the symptomology of IBD (Filipovic & Filipovic, 2014).  19 
The association between the alexithymia subtest “difficulty identifying 20 
feelings” and poor HRQoL in people with IBD has also been found in previous 21 
research (Iglesias-Rey et al., 2012). It has been suggested that an individual’s 22 
difficulty in effectively identifying their own feelings can limit their ability to 23 
differentiate between psychological experiences, such as anxiety, and IBD 24 
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symptoms. As a result, IBD symptoms may be interpreted as an emotional 1 
response or emotions may be interpreted as a symptom of IBD. Therefore, 2 
people who have “difficulty identifying feelings” might be more likely to 3 
somaticize psychological experiences such as emotional distress, and 4 
potentially experience them as physical pain (Barbera et al., 2017; Sifneos, 5 
1996; Taylor, Bagby, & Parker, 1997).  6 
The significant relationship between neurotic defence style and a poor HRQoL 7 
has been identified in previous research (Barbera et al., 2017; Jordan et al., 8 
2016; Hyphantis et al., 2009; Moreno-Jimenez et al., 2007). The neurotic 9 
defence style includes thoughts and behaviours such as repression, isolation 10 
and denial which attempt to avoid the experience of painful emotions, such as 11 
shame and anxiety. Therefore, “difficulty identifying feelings” which may 12 
involve the misinterpretation of feelings, combined with more neurotic defence 13 
styles, can lead to an emotional detachment from the IBD symptoms and an 14 
inaccurate perception of the illness (Hyphantis et al., 2009; Moreno-Jimenez 15 
et al., 2007). 16 
Illness perceptions have been identified as being important in the IBD 17 
population (Dorrian et al., Knowles et al., 2013; Rochelle & Fidler, 2013). 18 
However, for this study, the lack of a significant relationship between illness 19 
perceptions and HRQoL is potentially due to only a subtest of the BIPQ being 20 
investigated. Therefore, it is potentially the case that the inclusion of only the 21 
illness focussed perceptions, without the consequence focussed perceptions, 22 
distorted the relationship with HRQoL.  23 
5.1 Future directions 24 
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A recent systematic literature review has identified that a small proportion of 1 
people with IBD have access to psychotherapy despite it being found to be 2 
effective in treating psychological issues (Tarricone et al., 2017).On the basis 3 
of this study, psychological interventions could be tailored to individual needs, 4 
and might benefit from focusing on emotion based psychoeducation to provide 5 
an in depth awareness and understanding of a person’s abilities to recognise 6 
individual emotions, the purpose and function of emotions and the positive and 7 
negative connotations associated with each.  8 
The Tarricone review (2017) also found that third wave psychotherapies that 9 
assist in developing a mind-body link are effective in improving adjustment 10 
outcomes. Such psychological therapy may contribute to encouraging a better 11 
awareness of emotional recognition and the importance of self-care in 12 
attempting to manage IBD as a chronic condition. 13 
5.2 Limitations 14 
It is theorised that Alexithymia has a multidimensional structure consisting of 15 
poor imagination, difficulty communicating feelings and difficulty recognising 16 
and identifying feelings. Due to these various dimensions, it is still not clear 17 
whether alexithymia can be measured by a single self-report assessment. It 18 
may be the case that a thorough assessment of all dimensions of alexithymia 19 
requires interviews with the participant and their family members. Therefore, 20 
to rely solely on a self-report assessment, in which participants have to be self-21 
aware of whether they have a good imagination or can recognise other 22 
people’s emotions, might result in participants not accurately reporting their 23 
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ability to do these things. Therefore, the measurement of alexithymia used in 1 
this study might not be accurate.  2 
Also, a participant’s mood at the time of completing the questionnaire might 3 
have influenced how illness perceptions, alexithymia, defence styles and 4 
alexithymia were reported. In the study we did not request to know the 5 
participants mood at the time of completing the questionnaire (e.g. anxiety 6 
measure). Therefore, a person who was feeling more anxious at the time of 7 
reporting might have also reported a lower HRQoL at the time. 8 
Similarly, the participant’s disease severity was also not requested as part of 9 
the questionnaire. Therefore, it is possible that the participants who were 10 
experiencing an active period of symptoms would have recorded a worse 11 
quality of life at this time. Whereas, participants who were not experiencing 12 
severe symptoms might have regarded their illness as manageable, which 13 
would have been reflected in the way illness perceptions, alexithymia, defence 14 
styles and HRQoL were reported.    15 
5.3 Summary 16 
These findings were similar to those recently found in the Barbera et al., (2017) 17 
study, suggesting that females who are recently diagnosed with IBD and have 18 
difficulty identifying feelings as well as a reliance on neurotic defence styles 19 
have a worse HRQoL. Therefore, it might be beneficial to conduct a screening 20 
at the time of diagnosis to identify this population and offer psychotherapy to 21 
assist with emotional care and long term HRQoL.  22 
 23 
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Table 1: Descriptive data for demographic information 1 
Demographic information (total sample 
size – 139 participants) 
N Percentage 
Age 
     18 – 19 
     20 – 29 
     30 – 39 
     40 – 49 
     50 – 59 
     60 – 69 


















     Male 








     Crohn’s Disease  
     Ulcerative Colitis 
     Both 












     19 and below 
     20 – 29 
     30 – 39 
































     50 – 59 





Other medical conditions 
     Yes 







Anxiety or depression named as other 
medical condition 
     Yes 









Colostomy or ileostomy 
     Yes 







Perceived cause of IBD 
     Stress or worry 
     Hereditary or genes 
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Table 2: Descriptive data for illness factor, alexithymia, defence styles and 1 
HRQoL measures 2 
Measures N Mean 
scores 
SD 
Illness factor subtest 








     TAS-20 Subscale 1 (difficulty 
identifying feelings) 
      
     TAS-20 Subscale 2 (difficulty 
describing feelings)  
     
     TAS-20 Subscale 3 (externally 
oriented thinking) 
      



































     Mature defence style total 
     Neurotic defence style total 
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Table 3: Relationship between illness factor, alexithymia, defence styles as 1 





r = -0.12 
p = 0.13 
Unclear vs 
colitis 
r = 0.01 
p = 0.89 
Both vs colitis r = -0.16 
p = 0.06 
Gender r = 0.14 
p = 0.10 
Age r = 0.05 
p = 0.54 
Time since 
diagnosis 
r = 0.14 
p = 0.10 
Other medical 
conditions 
r = 0.17 
p = 0.04 
Illness factor 
subscale 






r = -0.54,  
p =0.00 









































r = 0.21,  











Defence styles, alexithymia, illness perceptions, and HRQOL in IBD 
89 
 
Table 4: Multiple regression analysis for illness factor, alexithymia, defence 1 
styles with HRQoL total outcome score 2 
Measures Beta Sig 




Both vs colitis -0.07 0.29 
Gender  0.20 0.00 
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Technical appendix - Appendix A 12 
Demographics form 13 
Please respond to each item by checking it and/or writing your answer in the 14 
space provided 15 
1. Age?      ________ 16 
 17 
2. Gender? 18 
Male    19 
Female 20 




3. Are you diagnosed with…  2 
Ulcerative Colitis   3 
Crohn's disease 4 
Not clearly diagnosed with either  5 
 6 
4. What age were you when you were first diagnosed with inflammatory 7 
bowel disease?   8 
________ 9 
5. Do you have any other medical conditions?  10 
Yes        11 
No 12 
Please state…………………………………………………………. 13 
 14 
 15 
Appendix B 16 
 17 
 18 
Invitation letter 19 
Dear Sir or Madam, 20 
Crohn’s and Colitis UK (NI group) is collaborating with the School of 21 
Psychology at Queen’s University Belfast to conduct research on Inflammatory 22 
Bowel Disease.  As a member of Crohn’s and Colitis UK (NI group), you have 23 
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received this letter of invitation to offer you the opportunity to participate in this 1 
research project. 2 
Before you decide to take part in this study, it is important that you understand 3 
the purpose of the research study and what it involves for you. Please read 4 
carefully the information sheet on the following pages, and discuss it with 5 
friends and relatives if you like. 6 
There are also contact details for the researchers that are involved in the study 7 
at the bottom of the information sheet.  Please contact them if there is anything 8 
that is not clear, or if you would like more information about the research 9 
project.  They will be glad to offer any further information on the study. 10 
The Crohn’s and Colitis UK (NI group) will deliver the questionnaire pack to 11 
your home by post in the coming weeks.  If you would like to take part, please 12 
complete the questionnaire pack and return it to us using the free-post 13 
stamped addressed envelope provided.  14 
Crohn’s and Colitis UK (NI group) will not know whether or not you participated 15 
in the study, so please rest assured that your decision will not impact on the 16 
support provided to you by the group. 17 
 18 
Yours faithfully, 19 
 20 
Liam Reilly  21 
(Lead researcher) 22 
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  1 
 2 




Information about the 
study 
We would like to invite you to take 
part in our research study. Before 
you decide if you would like to take 
part we would like you to 
understand why the research is 
being done and what it would 
involve for you. Please take the 
time to go through this information 
sheet. Crohn’s and Colitis UK (NI 
group) will be sending out the 
questionnaire pack for you to 
complete in the coming weeks. 
What is the research about? 
 
Living with a chronic Illness such as 
Inflammatory Bowel Disease (IBD) can 
at times be difficult. Different people 
cope in different ways with the 
challenges of living with such a 
physical health problem. It is important 
to understand the various coping 
mechanisms that can impact on 
quality of life when living with IBD. 
Such an understanding would inform 
treatments that might be beneficial in 
the future.    
 
Aims of the Study: 
 
We are interested in exploring how 
various psychological coping 
mechanisms can impact on Quality of 
Life for individuals living with Crohn’s 
Disease or Ulcerative Colitis. 
 
Why have I been chosen? 
 
You have been invited to take part in 
this study because you have a 
diagnosis of either Crohn’s or 
Ulcerative Colitis and are aged 18 
years or over. Other individuals who 
are in a similar position have also 
been invited to take part. 
Do I have to take part? 
 
Your participation in this study is 
voluntary. It is your decision to 
complete the questionnaire pack or 
not. If you decide not to complete and 
return the pack you will not be 
contacted by the researchers again. 
 
What will I need to do? 
 
You will be asked to complete a short 
questionnaire and return the 
questionnaires to the Psychology 
Department at Queens University in 
the free-post stamped addressed 
envelope provided. You will not have 
to answer any questions you do not 
want to. If you want to ask any 
questions about any of the 
questionnaires or the study, please 
contact any of the research team. The 
questionnaire will take approximately 
25 minutes to complete. 
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Will the information I give be 
confidential? 
 
All information will be treated 
confidentially and stored securely on a 
password protected computer and will 
be accessed by the research team.  
Results from this study will be 
presented on a group basis rather 
than specific individuals, so your 
information will not be identifiable. 
 
What are the possible benefits of 
taking part in the research? 
 
There are no direct benefits for you 
but people that take part in research 
studies generally think of it as a 
positive experience. It can provide a 
chance for you to get your 







Is there any risk involved in taking 
part in the research? 
We do not expect that there will be 
any risks related to taking part in this 
study. However we are aware that 
sometimes talking about our 
experiences can be difficult but there 
are no known risks to taking part in 
this study. If someone did become 
upset or worried as a result of taking 
part we would like them to contact the 
research team so that support could 
be provided.  
What happens with the research? 
 
Information will be collected, 
anonymised and entered into a 
password-protected computer, 
ensuring all information remains 
confidential. Only the research team 
will have access to this information.  
The final report will be submitted to 
Queen’s University, Belfast. We also 
hope to publish the results of this 
study in a scientific journal and 
present findings to health 
professionals. If you take part in this 
study and would like a summary copy 
of the findings we would be happy to 
send you a copy when the summary 
has been completed. 
 
What happens next? 
 
The questionnaire pack will be sent 
out to your home in the coming weeks 
by the Crohn’s and Colitis UK (NI 
group). If you would like to take part, 
please complete the questionnaire 
pack and return it to us using the free-
post stamped addressed envelope 
provided.  
 
Research team contact details: 
 
Liam Reilly (Lead Researcher) 
Trainee Clinical Psychologist 
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Dr Martin Dempster 
Health Psychologist / Chartered 
Statistician, and Director of 
Education 
Tel: 028 9097 5652 
m.dempster@qub.ac.uk 
 
Dr Laura Thompson 
Clinical Psychologist 




Alternative independent support 
phone numbers: 
 
Crohn’s and Colitis 
Emotional support Tel: 0121 737 
9931 
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biological influences on individual behaviour through to studies of psychological 
interventions and treatments on individuals, dyads, families and groups, to investigations of 
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All papers published in The British Journal of Clinical Psychology are eligible for Panel A: 
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corresponding author will be asked to provide a CRediT contributor role to classify the role 
that each author played in creating the manuscript. Please see the Project CRediT website 
for a list of roles. 
• The main document must be anonymous. Please do not mention the authors’ names or 
affiliations (including in the Method section) and refer to any previous work in the third 
person. 
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that references are accurate and complete. Give all journal titles in full and provide DOI 
numbers where possible for journal articles. 
• SI units must be used for all measurements, rounded off to practical values if appropriate, 
with the imperial equivalent in parentheses. 
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• Authors are requested to avoid the use of sexist language. 
• Authors are responsible for acquiring written permission to publish lengthy quotations, 
illustrations, etc. for which they do not own copyright. For guidelines on editorial style, 
please consult the APA Publication Manualpublished by the American Psychological 
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If you need more information about submitting your manuscript for publication, please 
email Vicki Pang, Editorial Assistant (bjc@wiley.com) or phone +44 (0) 1243 770 410 (ex 434 
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5. Brief reports and comments 
These allow publication of research studies and theoretical, critical or review comments 
with an essential contribution to make. They should be limited to 2000 words, including 
references. The abstract should not exceed 120 words and should be structured under 
these headings: Objective, Method, Results, Conclusions. There should be no more than 
one table or figure, which should only be included if it conveys information more efficiently 
than the text. Title, author name and address are not included in the word limit. 
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Telephone: 0207 104 8037  
 
Please note: This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at 
NHS sites in England until 




14 November 2016 
 
Mr Martin Dempster 
School of Psychology, David Keir Building 










REC reference:  
IRAS project ID: 
 
Illness perceptions, defence styles, alexithymia and  
health-related quality of life in people with inflammatory 




The Proportionate Review Sub-committee of the London - Riverside Research 
Ethics Committee reviewed the above application on 16 November 2016. 
 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three 
months from the date of this favourable opinion letter. The expectation is that this 
information will be published for all studies that receive an ethical opinion but should you 
wish to provide a substitute contact point, wish to make a request to defer, or require 
further information, please contact the REC Manager Tina Cavaliere, 
nrescommittee.london-riverside@nhs.net. Under very limited circumstances (e.g. for 
student research which has received an unfavourable opinion), it may be possible to grant 
an exemption to the publication of the study. 






On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting documentation, 
subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
You should notify the REC once all conditions have been met (except for site approvals 
from host organisations) and provide copies of any revised documentation with updated 
version numbers. Revised documents should be submitted to the REC electronically 
from IRAS. The REC will acknowledge receipt and provide a final list of the approved 
documentation for the study, which you can make available to host organisations to 
facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given permission 
for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is available in the 
Integrated Research Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but no 
later than 6 weeks after recruitment of the first participant. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
Defence styles, alexithymia, illness perceptions, and HRQOL in IBD 
117 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, they 
should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be 
registered, however, in exceptional circumstances non registration may be permissible with prior 
agreement from the HRA. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of the 




The documents reviewed and approved were: 
 
Document  Version  Date 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors   05 August 2016 
only) [Evidence of indemnity]      
IRAS Checklist XML [Checklist_10112016]   10 November 2016 
     
Letter from sponsor [Sponsor letter]   05 August 2016 
    
Letters of invitation to participant [Invitation letter] 1 05 August 2016 
    
Non-validated questionnaire [Demographics form] 1 05 August 2016 
    
Other [Validated questionnaire 2: The Brief Illness Perceptions 1 05 August 2016 
Questionnaire – BIPQ]      
Other [Validated questionnaire 3: Defense Style Questionnaire – 1 05 August 2016 
DSQ -28]      
Other [Validated questionnaire 4: Inflammatory Bowel Disease 1 05 August 2016 
Questionnaire – IBDQ]      
Participant information sheet (PIS) [Information sheet ]  Version 1  05 August 2016 
     
REC Application Form [REC_Form_10112016]    10 November 2016 
     
Referee's report or other scientific critique report [Research panel   05 August 2016 
report]      
Research protocol or project proposal [Project proposal 5.8.16 1 05 August 2016 
version 1]      
Summary CV for Chief Investigator (CI) [Chief Investigator CV]   05 August 2016 
     
Summary CV for student [Student CV]   05 August 2016 
     
Summary CV for supervisor (student research) [PI CV]   05 August 2016 
    
Validated questionnaire [Toronto Alexithymia Scale - TAS-20] 1 05 August 2016 
      
 
Membership of the Proportionate Review Sub-Committee 
 




Statement of compliance 
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The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
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The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
•  Notifying substantial amendments 
•  Adding new sites and investigators  
•  Notification of serious breaches of the 
protocol  
•  Progress and safety reports  
•  Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 




The Health Research Authority is continually striving to provide a high quality service to all  
applicants and sponsors. You are invited to give your view of the service you have received and  
the application procedure. If you wish to make your views known please use the feedback form 





We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/ 
 
With the Committee’s best wishes for the success of this project.  
 
16/LO/2080 Please quote this number on all correspondence 
 
Yours sincerely  
 
Pp 






Enclosures: List of names and professions of members who took part in the review 
 
“After ethical review – guidance for researchers” 
 
Copy to: Ms Paula Tighe  
Ms Alison Murphy, Research & Development Office 
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London - Riverside Research Ethics Committee 
 





Name Profession Present Notes 
    
Miss Stephanie Ellis Former Civil Servant Yes  
    
Dr Margaret Jones (Chair) Retired General Yes  
 Practitioner   
    
Ms Julia  Williams Senior Producer Yes  
    
 





Position (or reason for attending) 
 
   
     
Miss Tina Cavaliere  REC Manager  
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Multiple Linear Regression Assumptions 1 
The plot tests the assumption of heteroscedasticity. The fact that there is no 2 
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To test the assumption of linearity, partial regression plots were presented. 1 
The assumption is met as the pattern of points look like a random scatter, 2 
and do not look like a curve.  3 
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The residuals of the regression are normally distributed. Normal distribution 1 
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Multicollinearity was checked by looking at VIF in the coefficients table 1 
following multiple regression. It is suggested that a VIF between 5 and 10, 2 
demonstrates correlation which could be a problem in using multiple 3 




















Mature defence style 1.78 
Neurotic defence style 1.69 
Immature defence style 1.63 
Illness perceptions 1.48 
  5 
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Reflective appendix 1 
I kept a reflective diary throughout the process of completing the research 2 
project. This was useful, as it provided an opportunity to reflect on the learning 3 
experiences throughout the course of the research. For these experiences, I 4 
have organised my reflections using Gibbs (1988) reflective cycle.  5 
Description: I found that both my initial large scale research project (LSRP) 6 
and my systematic literature review were not viable research options, and 7 
therefore had to be changed. My LSRP was changed after it became clear that 8 
I would not be able to get the participants to complete the study. The 9 
systematic literature review was changed prior to the write up, after I found that 10 
another researcher had published their proposal for the same systematic 11 
literature review, with the intention of publishing the full review the following 12 
month. Each of these changes led to me joining a new research team and 13 
developing a new project.  14 
Feelings and evaluation: Although at the time, I was frustrated and 15 
disappointed that I had worked hard on projects that would not be pursued until 16 
the end; I was pleased and relieved that I had recognised the problems with 17 
the projects before they caused me major issues later on. 18 
Analysis: My experiences of completing the large scale research project and 19 
the systematic literature review taught me about the reality of conducting 20 
research. My expectations were that my initial research project ideas would 21 
remain the same, from conception, to design to completion. However, I quickly 22 
learned that the reality of research is that it can collapse and not progress any 23 
further for reasons outside the researcher’s control. 24 
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Reflecting on these experiences, it has taught me the importance of being 1 
flexible with project ideas and being honest as early as possible with the wider 2 
team and myself, about the likelihood of it being completed. 3 
Conclusion: I have realised that there is not much that can be done to avoid 4 
these situations, and research is largely about accepting that these difficult 5 
situations might occur. However, in the future I will be more aware of the 6 
resources that I have available to me in assisting with this process.  7 
Reflecting on this, I feel a big factor that can assist in navigating such difficult 8 
situations when they do occur is having an experienced and supportive team. 9 
I was very fortunate to work with two passionate and motivated teams who 10 
offered honest and useful advice about each of the projects whilst also 11 
encouraging me to take the lead from design to completion. From these 12 
experiences, I reflected about the importance of recognising the skills, 13 
knowledge and expertise that each team member brings to a project. I also 14 
learned about the importance of listening to this knowledge in making difficult 15 
decisions, such as whether to change a project.  16 
I also reflected that it is important to trust my own skills. I feel that due to my 17 
interest in each of the completed projects, I was very motivated to research 18 
the topics, collect data and analyse the outcomes, with the hope of sharing this 19 
information with each of the populations.  20 
As well as this, throughout the completion of the research, I reflected that I 21 
have further developed my organisational skills and time management skills, 22 
by managing university assignments, research projects, and placements; to 23 
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maintain a healthy work-life balance which I feel is important to learn and 1 
maintain in my future career. 2 
Action plan: For my future research projects, it will be important for me to be 3 
aware of the possibility that a research project will collapse before it is 4 
completed, and to consider alternative approaches early on in the design 5 
process.  6 
In future work, it will also be important for me to trust my team and also myself 7 
in being able to re-design and complete a new project. Although, it is frustrating 8 
and disheartening when effort has been put in to a project that does not make 9 
it to completion, my experience from this project has taught me that it is the 10 
reality of robust research.  11 
I feel that I have learned a lot from the development and completion of these 12 
research projects, and although it has not always been a straight forward 13 
process, I feel that these experiences have taught me a lot about research and 14 
about myself. From these experiences, I feel I have progressed further in to a 15 
more adequate research- practitioner.  16 
 17 
 18 
 19 
 20 
 21 
 22 
